Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

Código QR

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

Epidemiological data have demonstrated a significant association between the presence of type 2 diabetes mellitus (T2DM) and the development of colorectal cancer (CRC). Chronic hyperglycemia, insulin resistance, oxidative stress, and inflammation, the processes inherent to T2DM, also play active rol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, Rosaria Vincenza Giglio, Marcello Ciaccio, Manfredi Rizzo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	insulin resistance hyperglycemia oxidative stress inflammation small dense LDL glucagon-like peptide-1 receptor agonists Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/d789fe012af54893836fdd938c2a60f2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee J, et al.
Publicado: (2019)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
por: Funch D, et al.
Publicado: (2021)

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment
por: Li C, et al.
Publicado: (2021)

The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016)

To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System
por: Yin J, et al.
Publicado: (2021)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
por: Minara S. Shamkhalova, et al.
Publicado: (2020)

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang P, et al.
Publicado: (2019)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
por: Gagik R. Galstyan, et al.
Publicado: (2017)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
por: Funch D, et al.
Publicado: (2018)

Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options
por: Ali A. Rizvi, et al.
Publicado: (2021)

Mechanisms of neuroprotective action of incretin mimetics
por: Timur Dmitrievich Vlasov, et al.
Publicado: (2016)

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
por: Orme ME, et al.
Publicado: (2017)

Incretins today: multiple effects and therapeutic potential
por: Oksana V. Tsygankova, et al.
Publicado: (2019)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021)

Corrigendum: Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
por: Angelo Avogaro
Publicado: (2018)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
por: Alexander Sergeevich Ametov
Publicado: (2015)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
por: Ekaterina Alekseevna Shestakova
Publicado: (2011)

Association between small dense low-density lipoprotein cholesterol and neuroimaging markers of cerebral small vessel disease in middle-aged and elderly Chinese populations
por: Xiaorong Yu, et al.
Publicado: (2021)

Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
por: Khoury Johad, et al.
Publicado: (2018)

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
por: Yanbin Dong, et al.
Publicado: (2021)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
por: Pearson S, et al.
Publicado: (2019)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
por: Nina A. Petunina, et al.
Publicado: (2018)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Elevated Glucagon-like Peptide-1 and a Th2 Shift May Support Reduced Prevalence of Thoracic Aortic Aneurysm in Patients with Diabetes
por: Stelia Ntika, et al.
Publicado: (2021)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day
por: Igor A. Sklyanik, et al.
Publicado: (2021)

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
por: A Pegah, et al.
Publicado: (2021)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
por: Juris J. Meier
Publicado: (2019)

Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
por: Marina V. Shestakova, et al.
Publicado: (2017)

Dipeptidylpeptidase-4 inhibitors in the treatment of diabetes mellitus. Possibilities of cardioprotection
por: Elena Nikolaevna Trunina, et al.
Publicado: (2011)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Mathematical modelling of root causes of hyperglycemia and hypoglycemia in a diabetes mellitus patient
por: Paul S. Mwita, et al.
Publicado: (2021)

Incretin-based therapy: renal effects
por: Anton Ivanovich Korbut, et al.
Publicado: (2016)

Sakharnyy diabet i gormonal'naya enterologiya: put' v prekrasnoe daleko?
por: Andrey Alexeevich Aleksandrov
Publicado: (2011)